ORLANDO, Fla. — A second phase 2 trial with the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has met the primary efficacy endpoints for the treatment of the skin manifestations of cutaneous ...
In a lupus treatment landscape that’s “poised for evolution” in the coming years, Ventus Therapeutics is looking to make a mark with an early-stage prospect that features desirable characteristics.
Rocket Pharmaceuticals' shares rallied ahead of the opening bell after the Food and Drug Administration lifted its clinical hold on the biotechnology company's Phase 2 trial of its RP-A501 treatment ...
Demonstrated a favorable safety and tolerability profile for VG-3927 across all cohorts, including elderly participants, with no serious adverse events reported. Achieved robust and dose-dependent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback